[Research Report] The Public Opinion Survey on Cancer Genomics and Precision Medicine (March 9, 2022)
date : 3/9/2022
Tags: NCDs, Precision Cancer Medicine, Survey on Healthcare in Japan
![[Research Report] The Public Opinion Survey on Cancer Genomics and Precision Medicine (March 9, 2022)](https://hgpi.org/en/wp-content/uploads/sites/2/cancer-survey2021-top_ENG.jpg)
On March 9, 2022, Health and Global Policy Institute (HGPI) released poll data on public opinion about priorities for policies related to cancer genomics and precision medicine.
The new poll, conducted in October over the internet, asked a series of policy-related questions to a group of 1,000 people, selected without exclusion from a monitor panel of a research firm to be representative of the total population of Japan in terms of age, sex, and region.
Research asked participants about their own or family experience with cancer, and about their awareness and understanding of cancer genomics and precision medicine. Most people said that they had no experience with cancer (77.1%), while 10.4% said that someone in their family has had cancer, 3.4% said they themselves have had cancer, 1.5% said that they and someone in their family have had cancer. The remaining 7.6% stated that they preferred not to answer.
In terms of awareness and understanding, 57.2% said that they had never heard of cancer genomics or precision medicine, while 38.6% said they had heard of these treatments but did not know much about them. Just 4.2% said that they felt they were knowledgeable about this topic.
Results related to awareness and understanding were low regardless of cancer history, with an average of only approximately 55% reporting that they have at least heard of cancer genomics or precision medicine.
Respondents were asked about their prior knowledge of the six characteristics of cancer genomics and precision medicine listed below. Regardless of reported understanding about these topics, prior understanding about genomic testing, the timing of testing, and insurance coverage was particularly low. Even among those who reported having high knowledge of cancer genomics and precision medicine (42 respondents), just 9 (21.4%) answered that they knew all of the following points prior to this survey, further suggesting a need for greater awareness raising on this topic.
1. You can’t receive precision medicine at every hospital
2. Genomic tests investigate dozens to hundreds of genomic changes all at once, providing results about the specific characteristics of the patient’s cancer. This allows research into the best treatment for each patient.
3. Only a portion of genomic tests are covered by insurance
4. Genomic tests can only be done at specific time points
5. The probability of a genomic test being able to identify the best treatment for a patient is limited
6. Genomic tests can determine the possibility of a cancer having genomic causes
HGPI will continue to work to raise awareness and advance policy around cancer genomics and precision medicine through its work on non-communicable diseases.
For more information on this project and recent events on it organized by HGPI, please see here.
Top Research & Recommendations Posts
- [Research Report] The 2023 Public Opinion Survey on Satisfaction in Healthcare in Japan and Healthcare Applications of Generative AI (January 11, 2024)
- [Policy Recommendations] Cancer Control Project “Policy Recommendations on Addressing Regional Disparities in Breast Cancer Care” (January 31, 2025)
- [Research Report] The 2025 Public Opinion Survey on Healthcare in Japan (March 17, 2025)
- [Policy Recommendations] Achieving a Sustainable Society of Health and Longevity Through the Integration of Environment and Healthcare-Incorporating a Planetary Health Perspective into the 3rd Phase of The Healthcare Policy-(December 20, 2024)
- [Discussion Points] Intractable & Rare Diseases Project Discussion Paper “Intractable & Rare Diseases 2025: 10 Years After the Passing of the Intractable Diseases Act, Toward a Co-created Future” (Mar 28, 2025)
- [Policy Recommendations] Obesity Control Promotion Project 2023 “The Next Steps for Engaging and Cooperating with Patients, Citizens, and Communities for Implements of Obesity Control Measurements” (April 8, 2024)
- [Policy Recommendations] Developing a National Health and Climate Strategy for Japan (June 26, 2024)
- [Announcement] HGPI Endorsed “Civil Society’s Expectations for the Continuation and Development of Japan’s Global Health Initiatives” (March 17, 2025)
- [Research Report] Building a Mental Health Program for Children and Measuring its Effectiveness (June 16, 2022)
- [Public Comment Submission] “Plan for Global Warming Countermeasures (Draft)” (January 26, 2025)
Featured Posts
-
2025-03-26
[Registration Open] (Webinar) The 132nd HGPI Seminar “Considering the Ideal Evidence-Based Immunization and Vaccination Policies” (April 25, 2025)
-
2025-04-02
[Registration Open] Public Event “The Patient and Citizen Lived Experience Forum 2025” (May 17, 2025)
-
2025-04-17
[Registration Open] (Webinar) The 134th HGPI Seminar “Understanding Evidence-Based Dietary Guidelines: Leveraging the Dietary Reference Intakes for Japanese” (May 28, 2025)
-
2025-04-23
[Registration Open] Recruitment of the Health Policy Academy the 14th Session (Starts July 2025)
-
2025-04-23
[HGPI Policy Column] (No.58) — From the Global Health Strategy Project — “Toward Fair Health Systems: The Power of Data in Advancing UHC and Supporting Health Financing”